Acromegaly: the effect of somatostatin analogues on tumour volume shrinkage
Journal Title: OncoReview - Year 2016, Vol 6, Issue 4
Abstract
Acromegaly is a rare disease, caused by growth hormone (GH) hypersecretion and secondarily elevated insulin-like growth hormone 1 (IGF-1) level. Nearly all patients with acromegaly suffer from somatotroph pituitary adenoma. The main goal of treatment is to normalise both GH and IGF-1 levels, which reduces symptoms, complications and mortality. Transsphenoidal selective adenomectomy performed by an experienced neurosurgeon is the first-line therapy of choice. Therapy with somatostatin analogues (SSA) is used as a neoadjuvant treatment prior to surgery and in a persistent disease following the surgery.
Authors and Affiliations
Przemysław Witek, Marta Gutowska
Keywords
Related Articles
- EP ID EP186904
- DOI 10.5604/01.3001.0009.5058
- Views 228
- Downloads 0
Carcinosarcoma of the uteri as a third diagnosed malignancy - case report and the review of treatment modality
Progress in metastatic renal cell carcinoma treatment is generally based on new registered drugs. This brings improvement of results but it also needs the choice of proper drug. The decision is especially important in in...
Application of molecular markers in the diagnostics of thyroid focal lesions – current state of knowledge
Thyroid nodular disease is a common disorder and affects about 20% of adult polish population. Due to the fact that methods currently applied in routine assessment of these changes often do not provide accurate diagnosis...
Chemotherapy-related nephrotoxicity
The development of oncology and increasing prevalence of cancer is associated with rapidly growing group of patients treated with chemotherapeutic agents, which, with the benefits of their use, poses a risk of side effec...
Leczenie nadpłytkowości samoistnej w ciąży - doświadczenia własne ośrodka
Nadpłytkowość samoistna (ET) jest przewlekłym nowotworem mieloproliferacyjnym dotyczącym głównie linii megakariocytów, przebiegającym ze zwiększoną ponad 450 000/ul liczbą płytek krwi. Nadpłytkowość występuje przede wszy...
The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients – single centre experience
Introduction: Tyrosine kinase inhibitors (TKI) are the standard of treatment in patients with advanced non-small cell lung cancer (NSCLC) with EGFR (endothelial growth factor receptor) gene activating mutation. Objecti...